Oxidative stress and inflammation in lean and obese subjects with polycystic ovary syndrome

Journal of Reproductive Medicine

Volumn 58, Issue 3-4, 2013, Pages 107-114

  Blair, Sarah A ^a,b   Kyaw Tun, Tommy ^a,b   Young, Ian S ^a,b   Phelan, Niamh A ^a,b   Gibney, James ^a,b   McEneny, Jane ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Obesity; Polycystic ovarian syndrome; Serum amyloid A

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; MYELOPEROXIDASE; NEOPTERIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TROLOX C;

ADULT; AGE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY MASS; COMORBIDITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

ADULT; ANALYSIS OF VARIANCE; ANTIOXIDANTS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION; NEOPTERIN; OBESITY; OXIDATIVE STRESS; PEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; SERUM AMYLOID A PROTEIN; STATISTICS, NONPARAMETRIC;

EID: 84876429484     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Carmina E, Lobo RA: Polycystic ovary syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897-1899
2. Srikanthan P, Korenman S, Davis S: Polycystic ovarian syndrome: The next cardiovascular dilemma in women? Endocrinol Metab Clin North Am 2006;35:611-631
3. Sabuncu T, Vural H, Harma M, et al: Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001;34:407-413
4. Fenkci V, Fenkci S, Yilmazer M, et al: Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80:123-127
5. Diamanti-Kandarakis E, Paterakis T, Kandarakis HA: Indices of low-grade inflammation in polycystic ovary syndrome. Ann N Y Acad Sci 2006;1092:175-186
6. Halliwell B, Chirico S: Lipid peroxidation: Its mechanism, measurement, and significance. Am J Clin Nutr 1993;57: 715S-724S; discussion 724S-725S
7. Gonzalez F, Rote NS, Minium J, et al: Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:336-340
8. Verit FF, Erel O: Oxidative stress in non-obese women with polycystic ovary syndrome: Correlations with endocrine and screening parameters. Gynecol Obstet Invest 2008;65: 233-239
9. Sampson M, Kong C, Patel A, et al: Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 1996;45:623-629
10. Atiomo WU, Fox R, Condon JE, et al: Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol 2000;52:487-492
11. Kelly CC, Lyall H, Petrie JR, et al: Low-grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-2455
12. Boulman N, Levy Y, Leiba R, et al: Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89: 2160-2165
13. Orio F Jr, Palomba S, Cascella T, et al: Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed Online 2004;9:505-510
14. Talbott, EO, Zborowski JV, Boudreaux MY, et al: The relationship between C-reactive protein and carotid intimamedia wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:6061-6067
15. Francisco G, Hernandez C, Simo R: Serum markers of vascular inflammation in dyslipidaemia. Clin Chim Acta 2006;369: 1-16
16. Young IS, McEneny J: Lipoprotein oxidation and atherosclerosis. Biochem Soc Trans 2001;29:358-362
17. Ledochowski M, Murr C, Widner B, et al: Association between insulin resistance, body mass and neopterin concentrations. Clin Chim Acta 1999;282:115-123
18. Barutcuoglu B, Bozdemir AE, Dereli D, et al: Increased serum neopterin levels in women with polycystic ovary syndrome. Ann Clin Lab Sci 2006;36:267-272
19. Poitou C, Viguerie N, Cancello R, et al: Serum amyloid A: Production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 2005;48:519-528
20. Chait A, Han CY, Oram JF, et al: Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: Markers or mediators of cardiovascular disease? J Lipid Res 2005;46:389-403
21. Dunaif A: Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endo Reviews 1997;18:774-800
22. Phelan N, O'Connor A, Kyaw-Tun T, et al: Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab 2010;9:3933-3939
23. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-3672
24. Miller KK, Rosner W, Lee H, et al: Measurement of free testosterone in normal women and women with androgen deficiency: Comparison of methods. J Clin Endocrinol Metab 2004;89:525-533
25. Nadeem N, Woodside JV, Kelly S, et al: The two faces of 2 and aatocopherols: An in vitro and ex vivo investigation into VLDL, LDL and HDL oxidation. J Nutr Biochem 2011;23:845-851
26. Erel O: A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004;37:277-285
27. Erel O: A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-1111
28. Haffner SM: The metabolic syndrome: Inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006;97:3A-11A
29. Legros RS: Polycystic ovary syndrome: Long term sequelae and management. Minerva Ginecol 2002;54:97-114
30. Diamanti-Kandarakis E, Christakou C: Diagnosis and management of polycystic ovary syndrome. Springer US, SpringerLink, 2009, pp 1-266
31. Dandona P, Mohantry P, Ghanim H, et al: The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation and protein carbonylation. J Clin Endocrinol Metab 2001;86:355-362
32. Gonzalez F, Thusu K, Abdel-Rahman E, et al: Elevated serum levels of tumor necrosis factor alpha in normal weight women with polycystic ovary syndrome. Metabolism 1999; 48:437-441
33. Hak AE, Stehouwer CDA, Bots ML, et al: Association of Creactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy middle-aged women. Arterio Throm Vasc Bio 1999;19:1986-1999
34. Anfosso FN, Chomiki MC, Alessi P, et al: Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. J Clin Invest 1993;91:2185-2193
35. Nicholls SJ, Hazen SL: Myeloperoxidase and cardiovascular disease. Arterio Throm Vasc Bio 2005;25:1102-1111
36. Nijhuis J: Bariatic surgery and its effects on the metabolic and inflammatory aspects of morbid obesity. Chapter 6 of Academic Dissertation presented to the University of Maactrich, 2008, pp 82-92
37. Murr C, Widner B, Wirleitner B, et al: Neopterin as a marker for immune system activation. Curr Drug Metab 2002;3:175-187
38. Horejsi R, Moller R, Rackl S, et al: Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: Comparison with type 2 diabetic women. Am J Phys Anthropol 2004;124:275-281